ClinicalTrials.gg

Program

maridebart cafraglutide

Also written as “Maridebart cafraglutide”, “Maridebart Cafraglutide” and “AMG 133”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Sleep Apnea, Obstructive · Liver Diseases, led by Amgen.

Furthest: phase 3, since Feb 28, 202532 company-led studies, 19 open or runningNext primary completion: Nov 18, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen3219 open or runningphase 3since Feb 28, 2025Jul 16, 2020Nov 18, 2026phase 1 · NCT07523711

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Jul 16, 2020.

  1. Aug 29, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07160257 · 56 enrolled · United States
  2. Nov 5, 20252 phase 3 studiesNCT07225686, NCT07226765
  3. Nov 7, 20252 phase 1 studies in OverweightNCT07226778, NCT07229157
  4. Dec 16, 20252 phase 1 studies in OverweightNCT07310563, NCT07313761
  5. Feb 6, 2026Phase 2 study in OverweightNCT07441252 · 180 enrolled · United States
  6. Feb 18, 20263 phase 1 studiesNCT07429045, NCT07429032, NCT07428525
  7. Apr 6, 2026Phase 1 study in OverweightNCT07523711 · 49 enrolled · United States
  8. May 4, 2026Phase 3 study in ObesityNCT07575399 · 300 planned · United States, Puerto Rico
  9. Jun 29, 20262 phase 3 studies in ObesityNCT07684235, NCT07684144
  10. Jul 16, 2026Phase 1 study in OverweightNCT07717814 · 154 enrolled · United States
  11. Sep 16, 2026Phase 1 study in OverweightNCT07832799 · 340 planned
  12. Oct 5, 20262 phase 3 studiesNCT07866066, NCT07871409
  13. Oct 27, 2026Phase 1 study in ObesityNCT07908316 · 180 planned · United States
  14. Nov 2, 2026Phase 1 study in ObesityNCT07921316 · 356 planned

Ahead

  1. Nov 15, 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07160257
  2. Nov 18, 2026Primary completion: phase 1 study in OverweightNCT07523711
  3. Jan 21, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT06858878
  4. Jan 21, 2027Primary completion: phase 3 study in ObesityNCT06858839

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 32 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07921316Obesity1Not yet recruitingJul 26, 2027356
NCT07908316Obesity · United States1RecruitingDec 20, 2027180
NCT07871409Obesity · United States, Puerto Rico3RecruitingJun 16, 2027230
NCT07866066Diabetes Mellitus, Type 2 · United States, Canada3RecruitingSep 6, 20281,300
NCT07832799Overweight1Not yet recruitingMar 23, 2027340
NCT07717814Overweight · United States1CompletedMay 22, 2025154
NCT07684235Obesity · United States, Australia, Canada and more3RecruitingDec 26, 20273,200
NCT07684144Obesity · United States, Canada, Japan and more3RecruitingDec 26, 2027950
NCT07575399Obesity · United States, Puerto Rico3RecruitingJan 3, 2028300
NCT07523711Overweight · United States1Active, not recruitingNov 18, 202649
NCT07428525Liver Diseases · United States1CompletedFeb 26, 202636
NCT07429045Overweight · United States1CompletedNov 21, 202544
NCT07429032Overweight · United States1CompletedNov 26, 202557
NCT07441252Overweight · United States2Active, not recruitingAug 25, 2027180
NCT07313761Overweight · United States1CompletedJul 2, 2026349
NCT07310563Overweight · United States1CompletedMay 9, 202559
NCT07229157Overweight · United States1CompletedAug 27, 202681
NCT07226778Overweight · United States1CompletedMay 28, 2026348
NCT07226765Sleep Apnea, Obstructive · United States, Australia, Brazil and more3Active, not recruitingAug 30, 2027250
NCT07225686Obesity · United States, Australia, Brazil and more3Active, not recruitingAug 20, 2027250
NCT07160257Diabetes Mellitus, Type 2 · United States1Active, not recruitingNov 15, 202656
NCT07037459Obesity · United States, Argentina, Australia and more3RecruitingJun 30, 20285,056
NCT07037433Atherosclerosis · United States, Argentina, Australia and more3Active, not recruitingJun 30, 202812,800
NCT06976372Overweight · United States1CompletedDec 27, 2024120
NCT06987695Overweight · Japan3Active, not recruitingApr 27, 2027279
NCT06858878Diabetes Mellitus, Type 2 · United States, Argentina, Bulgaria and more3Active, not recruitingJan 21, 20271,105
NCT06858839Obesity · United States, Argentina, Australia and more3Active, not recruitingJan 21, 20273,853
NCT06660173Diabetes Mellitus, Type 2 · United States, Austria, Greece and more2Active, not recruitingOct 6, 2025409
NCT06352892Obesity · Hong Kong1CompletedAug 27, 202420
NCT05669599Obesity · United States, Australia, Canada and more2CompletedOct 8, 2024592
NCT05056246Healthy Participants · United States1CompletedApr 8, 202234
NCT04478708Obesity · United States1CompletedNov 18, 2022110

How it is read

Names in the registry

  • “Maridebart cafraglutide”, 12 entries
  • “Maridebart Cafraglutide”, 12 entries
  • “AMG 133”, 6 entries
  • “AMG 133 (frozen liquid)”, 1 entry
  • “AMG 133 (liquid)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.